Praxis Precision Medicines (NASDAQ:PRAX) Director Jill Desimone Sells 11,600 Shares

Posted by George Bondi on Jun 26th, 2026

Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) Director Jill Desimone sold 11,600 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $311.32, for a total transaction of $3,611,312.00. Following the completion of the sale, the director directly owned 2,337 shares in the company, valued at $727,554.84. This represents a 83.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Praxis Precision Medicines Stock Performance

NASDAQ PRAX traded down $0.07 on Friday, reaching $327.79. The company had a trading volume of 2,060,205 shares, compared to its average volume of 488,008. The company’s fifty day moving average is $314.27 and its 200-day moving average is $307.37. The firm has a market capitalization of $9.14 billion, a price-to-earnings ratio of -24.52 and a beta of 2.71. Praxis Precision Medicines, Inc. has a 1-year low of $37.19 and a 1-year high of $366.52.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($3.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.58) by $0.38. On average, research analysts forecast that Praxis Precision Medicines, Inc. will post -14.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $510.00 target price on shares of Praxis Precision Medicines in a research report on Tuesday, April 14th. HC Wainwright reduced their price target on Praxis Precision Medicines from $1,245.00 to $1,201.00 and set a “buy” rating for the company in a research report on Tuesday, June 2nd. Royal Bank Of Canada began coverage on shares of Praxis Precision Medicines in a research note on Wednesday, June 17th. They set an “outperform” rating and a $449.00 price target for the company. Oppenheimer reiterated an “outperform” rating and issued a $650.00 price objective (down from $750.00) on shares of Praxis Precision Medicines in a report on Tuesday, June 2nd. Finally, TD Cowen reissued a “buy” rating on shares of Praxis Precision Medicines in a research report on Tuesday, June 2nd. Four analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $566.21.

Check Out Our Latest Research Report on PRAX

Hedge Funds Weigh In On Praxis Precision Medicines

A number of institutional investors have recently added to or reduced their stakes in PRAX. NBC Securities Inc. bought a new stake in Praxis Precision Medicines during the fourth quarter worth $38,000. Parallel Advisors LLC grew its position in shares of Praxis Precision Medicines by 3,000.0% in the 1st quarter. Parallel Advisors LLC now owns 124 shares of the company’s stock valued at $40,000 after acquiring an additional 120 shares during the period. Danske Bank A S acquired a new position in shares of Praxis Precision Medicines during the 4th quarter worth about $59,000. GAMMA Investing LLC increased its stake in shares of Praxis Precision Medicines by 58.7% during the 4th quarter. GAMMA Investing LLC now owns 238 shares of the company’s stock worth $70,000 after purchasing an additional 88 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Praxis Precision Medicines by 24.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company’s stock valued at $77,000 after purchasing an additional 359 shares during the period. 67.84% of the stock is currently owned by institutional investors and hedge funds.

About Praxis Precision Medicines

(Get Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.